Olema Pharmaceuticals (OLMA) Retained Earnings (2020 - 2026)

Olema Pharmaceuticals (OLMA) has reported Retained Earnings for 7 consecutive years, with $1.1 billion the latest figure, recorded in Q1 2026.

• In Q1 2026, Retained Earnings rose 33.36% year-over-year to $1.1 billion; the TTM figure through Mar 2026 stood at $1.1 billion (up 33.36% YoY), while the FY2025 annual figure was $1.1 billion, up 347.18% from the prior year.
• Retained Earnings advanced to $1.1 billion in Q1 2026 per OLMA's latest filing, from $1.1 billion in the prior quarter.
• Across five years, Retained Earnings topped out at $1.1 billion in Q1 2026 and bottomed at -$509.3 million in Q2 2025.
• Historically, Retained Earnings has averaged $257.0 million across 5 years, with a median of $393.9 million in 2022.
• Annual changes were most pronounced in 2022 — Retained Earnings surged 2848357.14% — and 2024, when it tumbled 125490.78%.
• Olema Pharmaceuticals' Retained Earnings stood at -$209.0 million in 2022, then jumped by 100.17% to $347000.0 in 2023, then sank by 125490.78% to -$435.1 million in 2024, then jumped by 347.18% to $1.1 billion in 2025, then advanced by 5.22% to $1.1 billion in 2026.
• Business Quant data shows OLMA's Retained Earnings at $1.1 billion in Q1 2026, $1.1 billion in Q4 2025, and $858.5 million in Q3 2025.